ClinicalTrials.gg

Program

VX-407

A development code. Also written as “14C-VX-407”.

Its studies are mostly in Polycystic Kidney, Autosomal Dominant, led by Vertex Pharmaceuticals.

Furthest: phase 2, since Aug 29, 20256 company-led studies, 3 open or runningNext primary completion: Dec 15, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals63 open or runningphase 2since Aug 29, 2025Mar 28, 2024Dec 15, 2026phase 1 · NCT07868926

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2024First study: phase 1 study in Polycystic Kidney, Autosomal DominantFirst studyNCT06345755 · 159 enrolled · United States, Canada
  2. Jun 6, 2025Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07022119 · 32 enrolled · United States
  3. Jul 9, 2025Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07074327 · 74 enrolled · United States
  4. Aug 29, 2025Phase 2 study in Polycystic Kidney, Autosomal DominantNCT07161037 · 26 enrolled · United States, Belgium, Canada and more
  5. Aug 25, 2026Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07792408 · 148 planned · Canada
  6. Oct 5, 2026Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07868926 · 8 planned · United States

Ahead

  1. Dec 15, 2026Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07868926
  2. Mar 11, 2027Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07792408
  3. Jul 22, 2027Primary completion: phase 2 study in Polycystic Kidney, Autosomal DominantNCT07161037

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07868926Polycystic Kidney, Autosomal Dominant · United States1RecruitingDec 15, 20268
NCT07792408Polycystic Kidney, Autosomal Dominant · Canada1RecruitingMar 11, 2027148
NCT07161037Polycystic Kidney, Autosomal Dominant · United States, Belgium, Canada and more2Active, not recruitingJul 22, 202726
NCT07074327Polycystic Kidney, Autosomal Dominant · United States1CompletedFeb 20, 202674
NCT07022119Polycystic Kidney, Autosomal Dominant · United States1CompletedFeb 24, 202632
NCT06345755Polycystic Kidney, Autosomal Dominant · United States, Canada1CompletedJan 27, 2025159

How it is read

Names in the registry

  • “VX-407”, 6 entries
  • “14C-VX-407”, 1 entry

Codes read as this program: VX407.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.